DEXMETHYLPHENIDATE HYDROCHLORIDE | A078992 | PLATINUM PHARMACEUTICALS
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition Amendment from Senores Pharmaceuticals, Inc. FDA-2026-P-7183 · 8 docket documents Senores Pharmaceuticals, Inc. filed an amendment to a citizen petition requesting that FDA establish conditions of suitability under Section 505(i) for a generic drug product. The petition seeks regulatory guidance on manufacturing and formulation requirements necessary to support approval of an abb | Suitability | 2026-07-21 | Open | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$1.44
per ea
Lowest NADAC/Unit
$0.8519
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 49884043001DEXMETHYLPHENIDATE ER 30 MG CP | $1.44 | EA | Generic | — | 2026-10-21 |
| 49884042801DEXMETHYLPHENIDATE ER 15 MG CP | $0.8519 | EA | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.